| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | 1.1 | 0.1 |
| Profit before tax | -7.6 | -5.7 |
| Net income | -7.6 | -5.7 |
| EPS (diluted, $ a share) | $-0.05 | $-0.11 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +975.0% |
|---|
10-Q filed with the SEC, NASDAQ: IBIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
iBio, Inc.: key numbers
- Share price
- $0.7067Close, Nov 16
- Market cap
- $45.4M
- Shares outstanding
- 64.31MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from iBio, Inc.
All →iBio Clinical Trial Data
iBio announced extended preclinical data from a non-human primate study of IBIO-610, showing a 2.3% reduction in body weight and significant fat mass reduction over 28 weeks while maintaining lean mass. The company also disclosed preclinical data for its amylin program demonstrating selective receptor activation and reduced food intake in rat models. These results highlight the efficacy of iBio's AI-enabled antibody discovery platform in targeting obesity and cardiometabolic diseases.
iBio Financial Results
iBio reported financial results for its first fiscal quarter of 2027, highlighting a revenue increase to $1.1 million compared to $0.1 million in the prior year. The company advanced its obesity pipeline, completing dosing in the SAD portion of its Phase 1 trial for IBIO-600 and presenting preclinical data for IBIO-610 showing improved fat-selective weight loss in combination with GLP-1 therapy.
- Term
- Q1 2027
“This was a quarter of focus and execution as we advanced our portfolio of long-acting antibody therapeutics designed to address important challenges in obesity care. The data presented at EASD strengthen our conviction in IBIO-610’s potential to deliver high-quality weight loss and provide important preclinical validation as we advance toward an IND-equivalent filing by the end of 2026, with plans to initiate first-in-human studies in the first half of 2027.”
Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer
iBio Shareholder Meeting
iBio, Inc. held its 2026 Annual Meeting of Stockholders where shareholders approved an amendment to the 2023 Omnibus Incentive Plan to modify its 'evergreen' share increase provision through 2033. Stockholders also approved an increase in the number of authorized shares of common stock from 275 million to 500 million and re-elected two Class III directors to the Board.
iBio Clinical Trial Data
iBio released preclinical body-composition data from an eight-week obese non-human primate (NHP) study of its Activin E antibody candidate, IBIO-610. The study demonstrated that combining IBIO-610 with semaglutide resulted in 93% of weight loss coming from fat compared to 77% for semaglutide alone, suggesting significant muscle preservation potential. The company plans to initiate first-in-human clinical trials in the first half of 2027.
iBio Investor Presentation
iBio, Inc. has updated its corporate presentation for use in meetings with investors and analysts. The presentation, titled 'Breakthrough Antibodies for Obesity and Cardiometabolic Diseases', highlights the company's strategic focus and product candidate pipeline as of September 2026.